These innovative molecules represent a significant leap in the treatment of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in lowering blood glucose levels. https://tegandnfe502983.onesmablog.com/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide-80172006